Politics

Tom Marino Back in Running to Be Trump’s ‘Drug Czar’

Published on September 5, 2017 · Last updated July 28, 2020
Rep. Thomas Marino, R-Pa., flanked by House Speaker John Boehner of Ohio, left, and House Majority Leader Eric Cantor of Va., right, speaks during a news conference on Capitol Hill in Washington, Friday, Sept. 23, 2011. (AP Photo/Susan Walsh)

The White House has announced that President Donald Trump intends to nominate US Rep. Tom Marino to lead the Office of National Drug Control Policy (ONDCP).

Marino, an early supporter of then-candidate Trump, has been a candidate for the role—commonly known as White House “drug czar”—since at least April, when the president first said he intended to appoint the Pennsylvania Republican to the post. But Marino withdrew himself from consideration in May citing a critical illness in his family.

In the position, Marino would steer the administration’s policies on drug control. And as Leafly Deputy Editor Bruce Barcott reported in April, his record indicates he’s far more concerned with the country’s ongoing opioid epidemic than with regulated cannabis markets.

During his time in Congress, Marino has worked to expand access to treatment for individuals struggling with opioid addiction. He also led a successful legislative effort to address cross-border drug trafficking.  If those past examples are any indication, Marino would likely direct most of his attention as drug czar to America’s opioid crisis. A White House panel in July urged the president to declare a national emergency around opioid overdoses, which are estimated to have killed roughly 60,000 people in 2016.

Marino’s position on opioids, however, could raise concerns within the cannabis industry. He seems to favor tougher criminal enforcement on the ground and more leniency for drug manufacturers, an approach that echoes that of US Attorney General Jeff Sessions. In May 2016, for example, Marino suggested that authorities lock up nonviolent drug offenders in a “hospital-slash-prison,” with release dependent upon the treatment program’s approval. If, like Sessions, Marino sees cannabis as a contributor to America’s overdose epidemic—just last week, Sessions said the idea of legalizing cannabis “makes the hair stand up on the back of my neck”—he may be resistant to the growing body of evidence that medical cannabis can help combat the opioid crisis.

If confirmed by the Senate (which reconvened today), Marino would replace Richard Baum, the ONDCP’s acting head. His Congressional seat would need to be filled via a special election.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
Gage Peake
Gage Peake
Gage Peake is a former staff writer for Leafly, where he specialized in data journalism, sports, and breaking news coverage. He's a graduate of the University of Nebraska-Lincoln's College of Journalism and Mass Communications.
View Gage Peake's articles
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play




* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2024 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.